Incyte Corporation

NASDAQ (USD): Incyte Corporation (INCY)

Last Price

75.10

Today's Change

+0.48 (0.64%)

Day's Change

72.87 - 75.36

Trading Volume

707,095

Overview

Market Cap

14 Billion

Shares Outstanding

192 Million

Avg Volume

2,064,650

Avg Price (50 Days)

71.09

Avg Price (200 Days)

62.67

PE Ratio

834.89

EPS

0.09

Earnings Announcement

11-Feb-2025

Previous Close

74.62

Open

73.02

Day's Range

72.87 - 75.36

Year Range

50.35 - 83.95

Trading Volume

708,109

Price Change Highlight

1 Day Change

0.70%

5 Day Change

-0.75%

1 Month Change

-2.77%

3 Month Change

19.35%

6 Month Change

27.29%

Ytd Change

14.81%

1 Year Change

37.07%

3 Year Change

15.58%

5 Year Change

-20.06%

10 Year Change

-0.08%

Max Change

3907.47%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment